XML 28 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Jun. 30, 2017
Jun. 30, 2016
Cash flows from operating activities        
Net loss $ (7,917,720) $ (10,541,576) $ (22,508,304) $ (28,180,084)
Adjustments to reconcile net loss to cash provided by (used in) operating activities        
Depreciation, amortization and accretion 1,315,063 1,722,965 4,364,680 874,789
Asset impairment     1,265,125 7,500,000
Stock-based compensation expense 275,688 1,425,133 2,502,092 902,946
Issuance of restricted stock 103,635 156,814 724,613
Amortization of debt issuance costs     182,759
Amortization of beneficial conversion feature     4,943,073
Noncash interest expense     221,024
Derivative (income) (817,785) (196,148) (212,809) 12,572
Amortization of prepaid research and development - related party (Note 9) 60,992 335,454 121,983
Unrealized (gain) on investment (230,936) 61,519 971,629
Common stock issued to executives     509,996
Compensation through issuance of stock 509,996    
Issuance of warrants to initial investors 596,434 596,434
Gain on sale of asset     (428,374)
Warrant amendment     1,507
Adjustments to reconcile net loss to net cash used in operating activities:        
(Increase) in accounts receivable (849,397) (419,966) (355,031) (5,369)
(Increase) decrease in inventory (67,585) 85,741 195,427 (485,265)
(Increase) in prepaid expenses and other (454,595) (221,015) (95,202) 155,330
Increase (decrease) in accounts payable and other 1,124,558 (195,836) 493,217 698,237
(Decrease) in accrued liabilities (524,905) (238,395) (414,570) 925,232
Increase (decrease) in accrued compensation 497,586 (681,432) (861,226) 1,004,427
(Decrease) in deferred rent (3,337) (1,350) (4,200) 10,875
(Decrease) in deferred revenue     (511,607)
Net cash used in operating activities (7,318,794) (8,168,579) (13,829,652) (10,657,449)
Cash flows used in investing activities        
Purchases of property and equipment (12,195) (44,876) (111,608) (252,932)
Installment payment for Natesto asset (2,000,000) (6,000,000) (2,000,000)
Investment in Acerus     1,071,707 (2,012,991)
Sale of investment in Acerus cost     (91,864)
Sales of Primsol assets     1,750,000
Installment payment for Primsol asset (750,000) (750,000) (1,040,000)
Cash proceed from Nuelle     613,309
Cost related to Nuelle acquisition     (16,082)
Deposits     1,998
Net cash used in investing activities (12,195) (2,794,876) (3,534,538) (5,303,925)
Cash flows from financing activities        
Issuance of common stock to Lincoln Park Capital 631,481 739,857
Costs related to sale of common stock (24,247) (90,924)
Warrant tender offer     2,243,282
Warrant tender offer cost     (312,159)
Proceeds from convertible promissory notes, net (Note 8)     5,175,000
Debt issuance costs (Note 8)     (298,322)
Costs related to the conversion of the convertible promissory notes to equity     (29,754)
Ampio stock subscription payment     5,000,000
Registered offering 8,602,500 8,602,499 7,520,493
Registered offering costs (997,865) (997,865) (904,914)
Over-allotment warrants purchased by placement agents 2,852 2,852
Issuance of preferred, common stock and warrants 11,839,995    
Sale of stock subscription     200,000
Net cash provided by financing activities 10,437,164 8,214,721 10,187,542 16,662,503
Issuance costs related to preferred, common stock and warrants (1,402,831)    
Net change in cash, cash equivalents and restricted cash 3,106,175 (2,748,734) (7,176,648) 701,129
Cash, cash equivalents and restricted cash at beginning of period 877,542 8,054,190 8,054,190 7,353,061
Cash, cash equivalents and restricted cash at end of period 3,983,717 5,305,456 877,542 8,054,190
Non-cash transactions:        
Warrants issued to investors and underwriters (see Note 5) 4,117,997    
Revenue share payment to Jazz 7,385    
Earn-out payment to Nuelle Shareholders 250,000    
Issuance of common stock to Nuelle share holders     1,837,500
Fixed assets included in accounts payable 62,512 61,241 10,789
Warrants issued in connection with the equity financing to the placement agents $ 292,630 292,630
Warrants amended in connection with warrant tender offer     63,182
Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8)     102,931
Primsol asset purchase included in Primsol payable, $1,250,000 less future accretion of $173,000     1,077,000
Conversion of convertible promissory notes and interest of $221,000 to common stock     5,396,024
Natesto asset purchase included in Natesto payable, $6,000,000 less future accretion of $620,325     5,379,675
Warrant derivative liability related to the issuance of the registered offering placement agent warrants (Note 8)     297,317
Reclassification of liability based warrants to equity presentation related to the convertible promissory notes       136,828
Beneficial conversion feature related to convertible promissory notes     4,943,073
Debt issuance costs related to notes that converted to equity     $ (218,494)